Alembic Pharmaceuticals (ALPM) is a vertically integrated company with US trajectory catching up again backed by increased capacities and refilling pipeline post a lull after gAbilify. We expect US to contribute 31.9% by FY20E backed by own front-end launches. Recovery in the domestic business and improving margins (increasing chronic mix) to support future growth....